Tenofovir History

Tenofovir was initially actinic by Antonín Holý at the Institute of Organic Allure and Biochemistry, Academy of Sciences of the Czech Republic in Prague. The apparent filed by Holý in 1984 makes no acknowledgment of the abeyant use of the admixture for the analysis of HIV infection, which had alone been apparent one year earlier.

In 1985, De Clercq and Holy declared the action of PMPA adjoin HIV in corpuscle culture. Shortly thereafter, a accord with the biotechnology aggregation Gilead Sciences led to the analysis of PMPA's abeyant as a analysis for HIV adulterated patients. In 1997 advisers from Gilead and the University of California, San Francisco accustomed that tenofovir exhibits anti-HIV furnishings in bodies if dosed by subcutaneous injection.

The antecedent anatomy of tenofovir acclimated in these studies had bound abeyant for boundless use because it was not captivated if administered orally. A alleviative allure aggregation at Gilead developed a adapted adaptation of tenofovir, tenofovir disoproxil fumarate. This adaptation of tenofovir, which is the alone adaptation acclimated clinically today, is generally referred to artlessly as "tenofovir". In this adaptation of the drug, the two abrogating accuse of the tenofovir phosphonic acid accumulation are masked, appropriately acceptable articulate absorption.

Tenofovir disoproxil fumarate (TDF, Viread) was accustomed by the U.S. FDA on October 26, 2001, for the analysis of HIV, and on August 11, 2008, for the analysis of abiding hepatitis B.